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The renal glomerular basement membrane (GBM) contributes 
importantly to maintenance of the structural integrity of the glo-
merular capillaries (1, 2). Type IV collagen is the major component 
of the GBM, and its mutations have been linked to the genetic 
disorder Alport syndrome, a progressive hereditary kidney disease 
associated with sensorineural deafness (3). With a genetic frequen-
cy of about 1 in 5,000 people, it counts among the more prevalent 
of known genetic disorders (4). The disease is caused by the muta-
tions in any one of the genes encoding the α3, α4, and α5 chains 
of type IV collagen (COL4A3, COL4A4, and COL4A5) (5–7), and a 
mutation affecting 1 of these chains forming the α3/α4/α5(IV) 
collagen network can alter or abolish the GBM expression not only 
of the corresponding chain but also of the other 2 chains (8). The 
GBM in Alport syndrome instead retains the fetal α1/α1/α2(IV) 
collagen network (9), which confers an increased susceptibility 
to proteolytic enzyme, leading to progressive destruction of the 
GBM with subsequent hematuria and proteinuria, glomeruloscle-
rosis and ultimately end-stage renal disease. The current therapy is 
limited to dialysis and transplantation, with a higher risk of anti-
GBM disease in the transplanted organs due to immune reaction 
against the type IV collagen chains.
Bone morphogenetic protein–7 (BMP-7) is a promising candi-
date to treat Alport syndrome. BMP-7 belongs to the TGF-β super-
family (10), and the kidney is the major site of BMP-7 expression 
during both embryogenesis and postnatal development (11). Phar-
macological doses of BMP-7 can repair damaged renal tubules and 
preserve renal function in several models of renal diseases, includ-
ing the Col4A3 knockout model of Alport syndrome (12–20). 
However, the exact role of endogenous BMP-7 and its mechanism 
of action remain unclear. In addition, the administration of recom-
binant BMP-7, whose target cells are widely expressed throughout 
the body, might also produce some undesired extrarenal effect.
The local activity of endogenous BMPs is controlled by certain 
classes of binding molecules that act as positive or negative regula-
tors of BMP signaling activity (10, 21–24). BMP antagonists function 
through direct association with BMP, thus inhibiting the binding of 
BMP to its receptors and defining the boundaries of BMP activity.
The product of uterine sensitization–associated gene-1 (USAG-1) 
acts as a kidney-specific BMP antagonist, and USAG-1 binds to 
and inhibits the biological activity of BMP-7 (22, 25). USAG-1 is 
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Figure 1
Usag1–/–Col4a3–/– mice showed less glomerular and tubular injury. (A) Representative histological findings in Usag1+/+Col4a3–/– mice (WT/KO) 
and Usag1–/–Col4a3–/– mice (KO/KO) at 6 weeks and 10 weeks of age. Scale bars: 100 μm. (B and C) Quantitative assessment of the number 
of glomeruli, percentages of sclerotic and hemorrhagic glomeruli, and tubulointerstitial fibrosis score in Usag1+/+Col4a3–/– mice (WT/KO) and 
Usag1–/–Col4a3–/– mice (KO/KO) at 6 weeks (B, n = 5) and 10 weeks of age (C, n = 10). Bars indicate the mean ± SD. **P < 0.01; ***P < 0.05. (D) 
Electron microphotographs in Usag1+/+Col4a3–/– mice (WT/KO) and Usag1–/–Col4a3–/– mice (KO/KO) at 4 weeks and 10 weeks of age. Arrows 
indicate the splitting of GBM. Scale bars: 5 μm. (E) Immunostaining for α1(IV) and α3(IV) collagen in the glomeruli of WT littermates (WT/WT), 
Usag1+/+Col4a3–/– mice (WT/KO), and Usag1–/–Col4a3–/– mice (KO/KO) at 6 weeks of age. Podocin was used as a podocyte marker. Note the 
positive staining for α1(IV) collagen along with the GBM of Usag1+/+Col4a3–/– mice (WT/KO) and Usag1–/–Col4a3–/– mice (KO/KO), while the 
staining is restricted to mesangial areas in the glomeruli of WT littermates.
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expressed in distal tubules and colocalizes with BMP-7 in distal 
convoluted tubules and connecting tubules (26). Furthermore, 
Usag1–/– mice are resistant to tubular injury such as acute renal 
failure and interstitial fibrosis, and USAG-1 is the central negative 
regulator of BMP function in the adult kidney (27). Because in 
adults the expression of USAG-1 is confined to the kidneys, target-
ing the activity of this protein might yield safer and more kidney-
specific therapies than the administration of BMP-7 (23). For this, 
it will be important to first elucidate the role of USAG-1 in the 
pathology of progressive glomerular injury.
Here we show that genetic ablation of USAG-1 significantly attenu-
ated the disease progression and preserved renal function in Col4a3–/– 
mice, a model for human Alport syndrome. The observations in this 
study suggest that USAG-1 might contribute to the pathogenesis 
of renal deterioration by a mechanism we believe to be novel that 
involves crosstalk between the macula densa of the distal tubules and 
the mesangium of the belonging glomerulus. In addition, we demon-
strate that in the kidney of Col4a3–/– mice, TGF-β signaling includes 
phosphorylation of Smad1/5/8, transcription factors classically con-
sidered to be the downstream effectors of BMP signaling.
Results
Loss of USAG-1 slows progression of glomerular injury in Alport mice. 
Col4a3–/– mice, a mouse model of human Alport syndrome, devel-
op progressive glomerulonephritis associated with tubulointersti-
tial fibrosis leading to renal failure. Kidneys from Col4a3–/– mice 
showed irregular thickening and splitting of the GBM at 4 weeks 
of age by electron microscopy. At 5 weeks of age, proteinuria is 
initiated, and at 6 weeks of age, minor glomerular lesion is occa-
sionally observed by light microscopy. At 10 weeks of age, severe 
glomerular lesions associated with tubulointerstitial fibrosis are 
observed, and renal function deteriorates.
To test the role of USAG-1 in the progression of end-stage renal 
disease originating from glomerular injury, mice deficient in both 
Col4a3 gene and Usag1 gene were generated (Usag1–/–Col4a3–/– mice). 
A histological examination of the kidneys from Usag1+/+Col4a3–/– 
mice revealed segmental sclerosis and intraglomerular hemorrhage 
at 6 weeks of age, while these changes were almost completely 
absent in Usag1–/–Col4a3–/– mice (Figure 1, A and B). At 10 weeks of 
age, Usag1+/+Col4a3–/– mice demonstrated glomerulosclerosis associ-
ated with inflammatory cell infiltration, interstitial fibrosis, tubu-
lar atrophy, and cast formation, while these changes significantly 
decreased in Usag1–/–Col4a3–/– mice (Figure 1, A and C).
An ultrastructural analysis of GBM using transmission electron 
microscopy at 4 weeks of age showed that Usag1+/+Col4a3–/– mice had 
extensive splitting of the GBM, while Usag1–/–Col4a3–/– mice showed 
almost normal GBM structure (Figure 1D). Usag1–/–Col4a3–/– 
mice at 10 weeks of age also exhibited a significant preservation of 
GBM structure in comparison with age-matched Usag1+/+Col4a3–/– 
mice (Figure 1D).
The immunostaining of α1(IV) or α3(IV) collagen was performed 
to compare the glomerular localization of α(IV) collagen in both 
genotypes (Figure 1E). The expression of α1(IV) collagen was 
detected in the GBM of both Usag1+/+Col4a3–/– and Usag1–/–Col4a3–/– 
mice, while the expression was confined to mesangial area in the 
WT mice. The expression of α3(IV) collagen was absent in the 
GBM of both Usag1+/+Col4a3–/– and Usag1–/–Col4a3–/– mice, while the 
expression was detected along the GBM in the WT mice. Therefore, 
regardless of the presence or absence of USAG-1, no alteration was 
observed in the glomerular localization of α(IV) collagen.
Usag1–/–Col4a3–/– mice showed less albuminuria, preserved renal function, 
and longer life span. An analysis of urinary albumin excretion at 6 weeks 
of age is shown in Figure 2A, demonstrating significantly less albu-
minuria in Usag1–/–Col4a3–/– mice than in Usag1+/+Col4a3–/– mice. The 
systolic blood pressure of Usag1–/–Col4a3–/– mice at 5 weeks of age 
was slightly lower than that of Usag1+/+Col4a3–/– mice (Supplemental 
Figure 2; supplemental material available online with this article; 
doi:10.1172/JCI39569DS1). Renal function of Usag1–/–Col4a3–/– mice 
at 10 weeks of age, as assessed by serum creatinine and blood urea 
nitrogen, was also significantly preserved in comparison with that 
of Usag1+/+Col4a3–/– mice (Figure 2B), consistent with the results of 
renal histology and urinary albumin excretion. Furthermore, upon 
aging beyond 13 weeks, Usag1–/–Col4a3–/– mice showed less mortality 
than Usag1+/+Col4a3–/– mice (Supplemental Figure 1).
Inflammatory cytokine expression was significantly reduced in Usag1–/– 
Col4a3–/– mice. As previously reported, the mRNA of inflamma-
tory cytokines such as TNF-α, IL-1β, monocyte chemoattractant 
protein-1 (MCP-1), and TGF-β was upregulated in the kidneys of 
Usag1+/+Col4a3–/– mice at 10 weeks of age (28, 29). In Usag1–/–Col4a3–/– 
mice, however, increases in inflammatory cytokines were signifi-
Figure 2
Usag1–/–Col4a3–/– mice showed less albuminuria and preserved renal function. (A) Urinary albumin excretion normalized by urinary creatinine 
in WT littermates (WT/WT, n = 4), Usag1+/+Col4a3–/– mice (WT/KO, n = 8), Usag1+/–Col4a3–/– mice (HE/KO, n = 5), and Usag1–/–Col4a3–/– mice 
(KO/KO, n = 7) at 6 weeks of age. Open circles represent mean value of each column, while closed circles represent individual mice. (B) Plasma 
creatinine and blood urea nitrogen (BUN) levels in WT littermates (WT/WT, n = 20), Usag1+/+Col4a3–/– mice (WT/KO, n = 18), Usag1+/–Col4a3–/– 
mice (HE/KO, n = 34), and Usag1–/–Col4a3–/– mice (KO/KO, n = 17) at 10 weeks of age. Bars indicate mean ± SD. Open circles represent mean 
value of each column, while closed circles represent individual mice.
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cantly attenuated (Figure 3A). Immunostaining for MCP-1 revealed 
faint expression of MCP-1 in the glomeruli of Usag1–/–Col4a3–/– mice 
in comparison with Usag1+/+Col4a3–/– mice (Figure 3B).
Enhanced Smad1/5/8 phosphorylation in Usag1+/+Col4a3–/– mice, but not 
in Usag1–/–Col4a3–/– mice, was possibly activated by TGF-β signaling. Next, 
the activation of Smad signaling was examined. The traditional 
view of the TGF-β superfamily signaling pathways assumes 2 dis-
tinct branches: a TGF-β branch that signals through Smad2/3 and 
a BMP branch that signals through Smad1/5/8 (30).
We observed increased phosphorylation of Smad2, the TGF-β sig-
nal transducer, in the kidneys of Usag1+/+Col4a3–/– mice as compared 
with WT mice as well as Usag1–/–Col4a3–/– mice (Figure 4A), consistent 
with high expression of TGF-β in Usag1+/+Col4a3–/– mice (Figure 3A). 
The phosphorylation of Smad1/5/8, the classical BMP signal trans-
ducer, was expected to be reduced in the kidneys of Usag1+/+Col4a3–/– 
mice due to generally low expression of BMP-7 in kidney disease 
models (12, 17, 26, 31). However, the phosphorylation of Smad1/5/8 
was unexpectedly increased in the kidneys of Usag1+/+Col4a3–/– mice 
in comparison with WT mice as well as Usag1–/–Col4a3–/– mice.
Recently, several groups demonstrated that TGF-β activates 
Smad1/5 in addition to Smad2/3 in endothelial cells through novel 
receptor complexes (32–34). Thus, we hypothesized that the increased 
phosphorylation of Smad1/5/8 in the kidneys of Usag1+/+Col4a3–/– 
mice might also have resulted from high expression of TGF-β. To 
test this hypothesis, we administered TGF-β to various types of 
cells including MDCK cells, primary mesangial cells, NRK cells (rat 
tubule epithelial cells), NIH3T3 cells, and HeLa cells, and demon-
strated that TGF-β can activate the phosphorylation of Smad1/5/8 
in addition to Smad2 in all these cell types (Figure 4B). The phos-
phorylation of Smad1/5/8 was induced by TGF-β at concentrations 
as low as 1 ng/ml (Figure 4C). Furthermore, the phosphorylation of 
Smad1/5/8 in the kidneys of Usag1+/+Col4a3–/– mice correlated well 
with renal TGF-β as well as with serum creatinine levels, but not 
with the expression of BMP-7 (Figure 4D). Taken together, these 
results indicate that enhanced phosphorylation of Smad1/5/8 in 
Col4a3–/– mice might be due to TGF-β signaling and attenuated 
phosphorylation of Smad1/5/8 in Usag1–/–Col4a3–/– mice might 
reflect reduced expression of TGF-β and disease severity.
Usag1–/–Col4a3–/– mice showed less expression and activity of MMPs 
in the kidneys. Previous reports have demonstrated the important 
roles of MMPs in increasing susceptibility of defective Alport 
GBM to proteolytic degradation (9). The expression of MMP 
mRNA reported to be involved in this model was analyzed in 
the kidneys of 10-week-old mice, and this demonstrated strong 
upregulation of MMP-2, MMP-3, MMP-7, MMP-9, and MMP-12 
in the kidneys of Usag1+/+Col4a3–/– mice, while the expression of 
these MMPs was significantly less increased in the kidneys of 
Usag1–/–Col4a3–/– mice (Figure 5A). The proteolytic activity of 
these MMPs in the kidney extracts was also determined by casein 
and gelatin zymography. Casein zymography showed a signifi-
cant reduction in MMP-7 and MMP-12 activities (Figure 5B), 
and gelatin zymography demonstrated significant reduction of 
MMP-2 activity in the kidneys of Usag1–/–Col4a3–/– mice in com-
parison with Usag1+/+Col4a3–/– mice (Figure 5C). Also, the bands 
seen at 57 and 45 kDa in gelatin zymography, possibly represent-
ing MMP-3 activity (35), were significantly less in the kidneys of 
Usag1–/–Col4a3–/– mice. Recently, it was demonstrated that expres-
sion of MMP-12 was markedly upregulated in the glomeruli of 
Usag1+/+Col4a3–/– mice, and inhibition of MMP-12 preserved the 
integrity of GBM (29). Immunostaining for MMP-12 demonstrat-
ed a significant upregulation in the glomeruli and interstitium 
of Usag1+/+Col4a3–/– mice, while the induction was attenuated in 
Usag1–/–Col4a3–/– mice (Figure 5D). While MMP-12 is expressed by 
macrophages as well as glomerular cells such as podocytes (29, 36, 
37), immunostaining of CD11b, a marker of monocytes and tis-
sue macrophages, failed to demonstrate any significant infiltra-
tion of macrophages or monocytes in the glomeruli of 10-week-old 
Usag1+/+Col4a3–/– mice (data not shown), suggesting that the glo-
merular MMP-12 in Alport mice was not due to the macrophages 
that infiltrated the glomeruli.
Figure 3
The expression of inflammatory cytokines significantly decreased in the kidneys of Usag1–/–Col4a3–/– mice. (A) Real-time RT-PCR analysis of 
inflammatory cytokine mRNA in the kidneys of WT littermates (WT/WT), Usag1+/+Col4a3–/– mice (WT/KO), and Usag1–/–Col4a3–/– mice (KO/KO) 
at 10 weeks of age. The expression levels were normalized to those of GAPDH and expressed relative to those of WT littermates (n = 10). Bars 
indicate the mean ± SD. *P < 0.001; **P < 0.01; ***P < 0.05. (B) Representative immunostaining for MCP-1 in the kidneys of WT littermates 
(WT/WT), Usag1+/+Col4a3–/– mice (WT/KO), and Usag1–/–Col4a3–/– mice (KO/KO) at 10 weeks of age. Scale bars: 100 μm.
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USAG-1 was not expressed in the Alport glomeruli. USAG-1 is 
expressed predominantly in the distal tubules, more specifically, 
in the thick ascending limb, distal convoluted tubules, and con-
necting tubules in adult kidneys, and not expressed in glomeruli 
(26). In situ hybridization was used to determine the expression of 
USAG-1 in Usag1+/+Col4a3–/– mice and demonstrated that USAG-1 
expression was not detectable in the glomeruli of Usag1+/+Col4a3–/– 
mice either (Figure 6A) and was confined to tubules.
USAG-1 colocalizes with BMP-7 in the macula densa. Deficiency of 
USAG-1 significantly attenuated glomerular pathology in the 
Col4a3–/– mouse model of Alport syndrome in spite of the absence 
of USAG-1 expression in glomeruli. Further experiments focused 
on the part of the distal tubule that came in contact with its own 
glomerulus, the macula densa (Figure 6B). To determine whether 
USAG-1 is expressed in macula densa cells, we performed double 
staining of nNOS, a specific marker for macula densa, and β-gal 
using Usag1+/LacZ mice. As shown in Figure 6C, β-gal staining as 
well as immunostaining with anti-LacZ antibody colocalized with 
nNOS staining, indicating that USAG-1 was expressed in macula 
densa. BMP-7 is expressed in distal convoluted tubules, connect-
ing tubules, collecting ducts, and podocytes (26). β-gal staining 
as well as immunostaining with anti-LacZ antibody also colocal-
ized with nNOS in the kidneys of Bmp7+/LacZ mice, indicating the 
expression of BMP-7 in the macula densa (Figure 6C). Therefore, 
USAG-1 colocalizes with BMP-7 in the macula densa cells.
BMP-7 suppressed TGF-β–induced MMP-12 upregulation in mesangial 
cells, and USAG-1 antagonized the action of BMP-7. The macula densa, 
in which both USAG-1 and BMP-7 are expressed, is adjacent to 
mesangial cells in its own glomerulus (Figure 6B). To investigate 
potential mechanisms that are responsible for the beneficial effect 
of USAG-1 deficiency in Alport syndrome, the effect of BMP-7 and 
USAG-1 in cultured mesangial cells was examined. The expression 
of MMP-12 in cultured mesangial cells was upregulated by the 
administration of IL-1β and TGF-β, but not by the administration 
of MCP-1 (Figure 6D), in spite of the fact that MCP-1 is reported to 
stimulate MMP-12 expression in podocytes (29). The administra-
tion of BMP-7 suppressed TGF-β–induced MMP-12 upregulation 
in mesangial cells, and simultaneous administration of USAG-1 
antagonized the suppressive effect of BMP-7 (Figure 6E). These 
results indicate that USAG-1 might enhance MMP-12 expression 
in the glomeruli by suppressing the inhibitory effect of BMP-7 and 
exacerbate glomerular disease progression in Alport syndrome.
Discussion
This study demonstrates that USAG-1 accelerates glomerular 
pathogenesis in a mouse model of human Alport syndrome, pos-
sibly through the crosstalk between the kidney tubules and its own 
glomerulus. Usag1–/–Col4a3–/– mice demonstrated attenuated glo-
merular disease progression and preserved renal function in com-
parison with Usag1+/+Col4a3–/– mice and significantly decreased 
Figure 4
Smad1/5/8 phosphorylation was 
enhanced in Usag1+/+Col4a3–/– 
mice, but not in Usag1–/–Col4a3–/– 
mice. (A) Representative immu-
noblotting for Smad phosphory-
lation in the kidneys of WT lit-
termates (WT/WT), Usag1+/+ 
Col4a3–/– mice (WT/KO), and 
Usag1–/–Col4a3–/– mice (KO/KO) 
at 4 and 10 weeks of ages. (B) 
A panel of cell lines were tested 
for the ability of TGF-β to induce 
phosphorylation of Smad1/5/8 in 
addition to Smad2. Cells were 
either left untreated or stimulated 
with 4 ng/ml of TGF-β for 1 hour. 
Whole-cell extracts were analyzed 
by immunoblotting using anti-
bodies against phosphorylated 
Smad1/5 /8  (pSmad1/5 /8 ) , 
pSmad2, and GAPDH as a load-
ing control. (C) Representative 
immunoblotting showing the 
effect of various concentrations 
of TGF-β on the phosphorylation 
of Smad1/5/8 in MDCK cells. (D) 
Correlation between the phos-
phorylation levels of Smad1/5/8 in 
the kidneys of Usag1+/+Col4a3–/– 
mice and mRNA expression of 
TGF-β and BMP-7 and serum 
creatinine (n = 14). The levels 
of phosphorylation of Smad1/5/8 
were determined using the LAS 
image analysis system.
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expression and activity of MMPs, which play key roles in disease 
progression of Alport syndrome. Furthermore, USAG-1 and BMP-7 
colocalized in the macula densa, a part of the distal tubules in con-
tact with its own glomerulus, and BMP-7 reduced MMP-12 expres-
sion in mesangial cells, which was antagonized by USAG-1.
USAG-1 exacerbates glomerular injuries as well as tubular interstitial 
fibrosis. Tubular damage and interstitial fibrosis are the final com-
mon pathways leading to end-stage renal disease (ESRD) (38, 39) 
irrespective of the nature of the initial renal injury, and the degree 
of tubular damage parallels the impairment of renal function (39). 
Severe tubulointerstitial fibrosis is observed following glomeru-
lar injury in Col4a3–/– mice, and this exacerbates renal function. 
Because Usag1–/– mice were resistant to tubulointerstitial fibrosis 
(27), this resistance might contribute at least 
in part to the preservation of renal function 
in Usag1–/–Col4a3–/– mice. In addition, Usag1–/– 
Col4a3–/– mice showed preserved GBM with 
less albuminuria in the early stage when 
tubular injury has yet to appear. Therefore, 
Usag1–/–Col4a3–/– mice were resistant to both 
glomerular and tubular injuries.
USAG-1 increases the expression of MMP in 
Col4a3–/– mice. The molecular mechanisms by 
which the altered GBM composition in Alport 
syndrome causes renal pathogenesis remain 
unclear. It is proposed that abnormal persis-
tence of α1/α1/α2(IV) collagen network in the 
adult GBM is associated with increased sus-
ceptibility to proteolysis by proteases in Alport 
syndrome (3, 9) and pharmacological abla-
tion of MMP activities, especially MMP-12, 
leads to a significant attenuation in Alport 
disease progression (29, 40). The expression 
and activities of MMPs were significantly 
upregulated in the kidneys of Usag1+/+Col4a3–/– 
mice, which is consistent with previous 
reports, and they were suppressed in the kid-
neys of Usag1–/–Col4a3–/– mice. The suppression of MMP activities 
probably contributed, at least in part, to slow glomerular pathogene-
sis in Usag1–/–Col4a3–/– mice. In addition, the administration of BMP-7 
decreased the expression of MMP-12 in cultured mesangial cells, and 
USAG-1 antagonized the action of BMP-7. Therefore, USAG-1 might 
increase the expression of MMP in glomeruli and accelerate GBM 
destruction in Col4a3–/– mice.
Other possible roles of USAG-1 and BMP-7 in glomerular pathogen-
esis in Col4a3–/– mice. In addition to the inhibitory effect on MMP 
expression, BMP-7 possibly inhibits the progression of glomerular 
pathogenesis in Col4a3–/– mice at multiple steps. BMP-7 reduces 
the damage in podocytes (20, 41, 42) and mesangial cells (43–45) 
and attenuates the expression of inflammatory cytokines (46) and 
Figure 5
Usag1–/–Col4a3–/– mice showed less expres-
sion and activity of MMPs in the kidneys. (A) 
Real-time RT-PCR analysis of MMP mRNA 
in the kidneys of WT littermates (WT/WT), 
Usag1+/+Col4a3–/– mice, (WT/KO) and Usag1–/– 
Col4a3–/– mice (KO/KO) at 10 weeks of age. The 
expression levels were normalized to that of 
GAPDH and expressed relative to that in WT lit-
termates (n = 10). Bars indicate the mean ± SD. 
*P < 0.001; **P < 0.01. (B) Casein zymography 
analyzing the kidneys of WT littermates (WT/WT), 
Usag1+/+Col4a3–/– mice (WT/KO), and Usag1–/– 
Col4a3–/– mice (KO/KO) at 10 weeks of age. 
(C) Gelatin zymography analyzing the kidneys 
of WT littermates (WT/WT), Usag1+/+Col4a3–/– 
mice (WT/KO), and Usag1–/–Col4a3–/– mice 
(KO/KO) at 10 weeks of age. (D) Representative 
immunostaining for MMP-12 in the kidneys of 
WT littermates (WT/WT), Usag1+/+Col4a3–/– mice 
(WT/KO), and Usag1–/–Col4a3–/– mice (KO/KO) at 
10 weeks of age. Scale bars: 100 μm.
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apoptosis in several types of cells (12, 41). Antagonizing the benefi-
cial effects of BMP-7 by USAG-1 might enhance these injuries and 
accelerate glomerular pathogenesis in Alport syndrome.
USAG-1 secreted from distal tubules reaches the glomerulus and 
accelerates glomerular injury. Although the mechanism by which 
USAG-1 secreted from distal tubules reaches the glomerulus 
and exacerbates glomerular pathogenesis is not entirely clear, a 
crosstalk may exist between the distal tubule and the glomeru-
lus in the same nephron.
The distal tubule of a nephron makes contact with the vascular 
pole of its glomerulus from which the distal tubule originated. At 
this point, there is a plaque of very specialized and differentiated 
cells in the distal tubule known as the macula densa (Figure 6B). The 
macula densa detects changes in the distal tubular fluid composi-
tion and transmits signals to the adjacent extraglomerular mesan-
gial cells and afferent arterioles (47–53). Extraglomerular mesangial 
cells are anatomically in continuity with the glomerular mesangial 
cells and transmit the signal from the macula densa to the glomeru-
Figure 6
USAG-1 colocalizes with BMP-7 in the macula densa and inhibits the action of BMP-7 in mesangial cells. (A) In situ hybridization for USAG-1 
mRNA in the kidneys of 10-week-old Col4a3–/– mice. Scale bars: 100 μm. G, glomerulus. (B) A schematic illustration of the juxtaglomerular appa-
ratus. The macula densa is a part of distal tubules contacting with its glomerulus of origin and adjacent to mesangial cells. (C) β-Gal staining as 
well as immunostaining with anti-LacZ antibody colocalized with immunostaining with anti-nNOS (a marker for macula densa) antibody in the kid-
neys of Usag1+/LacZ mice and Bmp7+/LacZ mice. Kidney section from WT mice was also treated in the same way with the sections from Usag1+/LacZ 
mice and Bmp7+/LacZ mice and demonstrated no β-gal staining. Scale bars: 100 μm. (D) Real-time RT-PCR analysis of MMP-12 mRNA in cultured 
mesangial cells treated with inflammatory cytokines. The expression levels were normalized to those of GAPDH and expressed relative to those 
in controls. TGF-β markedly increased MMP-12 mRNA expression in mesangial cells. The graph reflects data that are representative for results 
of 4 independent experiments. (E) Real-time RT-PCR analysis of MMP-12 mRNA in cultured mesangial cells that were incubated with TGF-β, 
BMP-7, and USAG-1. BMP-7 suppressed TGF-β–induced MMP-12 upregulation in mesangial cells, and USAG-1 reversed the action of BMP-7. 
The graph reflects data that are representative for results of 4 independent experiments.
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lus. The signals from the macula densa to the mesangial cells involve 
small diffusible substances (ATP or adenosine) released from the 
macula densa (47, 54). Multiphoton imaging demonstrates the 
water flow across the macula densa into the mesangial cell field at 
varying osmolarities in the luminal fluid (47). The histological char-
acteristics of the macula densa also support the idea of substance 
transportation from the macula densa to mesangial cells: the nuclei 
of macula densa cells are apically located, while most of cell organ-
elles tend to be located basally and laterally, thus indicating that the 
substances from the macula densa are possibly secreted basolater-
ally (Figure 7A). In addition, the basement membrane of the macula 
densa is fused with the basement membrane of the extraglomerular 
mesangial cells, indicating the lack of a barrier to interfere with the 
substance transportation from the macula densa to the glomeru-
lus (Figure 7A). Furthermore, Hugo et al. demonstrated that extra-
glomerular mesangial cells function as reserve cells for glomerular 
mesangial cells (55). Extraglomerular mesangial cells stimulated by 
substances secreted from the macula densa migrate into glomerulus 
after glomerular injury and repopulate as mesangial cells.
As shown in Figure 6C, both USAG-1 and BMP-7 are expressed 
in the macula densa, and USAG-1 secreted from the basolateral 
membrane of macula densa could inhibit the action of BMP-7 on 
the adjacent mesangial cells. In the experiments using cultured 
mesangial cells, BMP-7 significantly attenuated TGF-β–induced 
MMP-12 upregulation, and the inhibitory effect of BMP-7 was 
abolished by the addition of USAG-1. Moreover, BMP-7 reduced 
TGF-β–induced cytotoxicity in mesangial cells (data not shown). 
Therefore, USAG-1 might exacerbate glomerular pathogenesis 
in Alport syndrome through accelerating upregulation of GBM-
degrading enzyme and cytotoxicity by inhibiting the reno-protec-
tive effects of BMP-7 (Figure 7B).
An alternative possibility that may explain the effect of USAG-1 
on glomerular injury is an interaction between circulating USAG-1 
and BMP-7 in plasma. BMP-7 is present in plasma at a concentra-
tion range of 100–300 pg/ml (12). Due to the lack of an effective 
ELISA system, the plasma level of USAG-1 remains to be deter-
mined. If an appropriate amount of USAG-1 is present in the cir-
culation, it could therefore bind to BMP-7 and thus inhibit its 
activity. To test the effect of circulating USAG-1 in the progres-
sion of Col4a3–/– mice, we performed systemic gene transfer of 
USAG-1 expression vector to Usag1–/–Col4a3–/– mice and demon-
strated that the difference in albuminuria between the gene trans-
fer group and the control group was not statistically significant 
(Supplemental Figure 3).
Novel therapeutic approach for Alport syndrome. At present there is 
no definitive therapy to prevent or slow renal disease progression 
in Alport syndrome. Several studies using a mouse model of Alport 
syndrome have provided potential therapies, such as MMP inhibi-
tor (29, 40), angiotensin-converting enzyme inhibitor (56), statins 
(57), transplantation of bone marrow–derived stem cells (58–60), 
and total body irradiation (61). The results of the present study 
support the notion that therapeutic trials to inhibit the function 
of USAG-1 may become a novel therapeutic approach for Alport 
syndrome either alone or in combination with other approaches. 
A therapeutic trial targeting USAG-1 is promising because it is 
expected to be effective in both glomerular and tubular injuries, is 
more kidney-specific, and has fewer extrarenal effects because the 
expression of USAG-1 is confined to the kidney.
Methods
Mice. The Usag1–/– mice used in this study have been described previ-
ously (27), and Col4a3–/– mice were purchased from Jackson Laboratory 
(JAX mice strain 129-Col4a3tm1Dec/J) (62). Usag1–/–Col4a3–/– mice were 
generated by breeding Usag1+/– and Col4a3+/– mice. Col4a3–/– littermates 
(Usag1+/+Col4a3–/– mice) and WT littermates (Usag1+/+Col4a3+/+ mice) 
served as controls. All animal studies were approved by the Animal 
Research Committee, Graduate School of Medicine, Kyoto University, 
and performed in accordance with the guidelines of Kyoto University. 
Figure 7
Hypothetical model for involvement of USAG-1 
secreted from distal tubules in the pathogenesis 
of glomerular damage in Alport syndrome. (A) The 
macula densa (red), a part of the distal tubules, 
lies beside the extraglomerular mesangial cells 
(green), and the nuclei of the macula densa cells 
are apically located, suggesting the possibility 
that substances (blue) might be secreted from the 
basolateral membrane of the macula densa. Note 
that the basement membrane of the macula densa 
cells is continuous with the basement membrane 
of the extraglomerular mesangial cells. (B) In 
Usag1+/+Col4a3–/– mice (WT/KO), the mesangial 
cells are activated (purple) and secrete MMPs 
(scissors), which degrade GBM. Following GBM 
destruction, podocytes residing on the GBM are 
damaged (brown) and albuminuria is observed. 
BMP-7 (blue) secreted from the macula densa is 
captured by USAG-1, which is also secreted from 
the macula densa. As a consequence, BMP-7 
cannot bind to its receptors and exert its renopro-
tective action. In Usag1–/–Col4a3–/– mice (KO/KO), 
BMP-7 secreted from the macula densa can bind 
to its receptors on mesangial cells and podocytes, 
and protect fragile alport GBM from degradation.
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Age-matched mice were used for all studies. The ages of mice used in 
each experiment are described below.
Assessment of albuminuria. The mice were placed in metabolic cages, and 
urine was collected over a 24-hour period. During the urine collection, mice 
were allowed free access to food and water. Urinary albumin concentration 
was measured using the Albuwell M assay kit (Exocell).
Renal histopathology and electron microscopy. The kidneys were fixed in 
Carnoy’s solution and embedded in paraffin. Sections (2-μm thick) were 
stained with PAS for routine histological examination, and the degree of 
morphological change was determined for ten 10-week-old mice and five 
6-week-old mice per group by experienced pathologists who were blinded to 
the genotypes. The following parameters were evaluated: percentage of hem-
orrhagic glomeruli and sclerotic glomeruli; and tubular atrophy/interstitial 
fibrosis score. Tubular atrophy/interstitial fibrosis was graded as follows: 
grade 0, 0%–24%; grade 1, 25%–49%; grade 2, 50%–74%; grade 3, ≥ 75%.
Frozen sections of the kidneys were immunostained as previously 
described (63). The primary antibodies were against podocin (64), α1 
(H11), and α3 (H31) chains of type IV collagen (a gift from Y. Sado; ref. 
65), MCP-1 (R&D Systems), MMP-12 (Santa Cruz Biotechnology Inc.), 
nNOS (Cayman Chemical and Abcam), and LacZ (Cappel Laboratory). 
For double staining with β-gal, immunostaining was performed before 
β-gal staining to avoid the possibility that the deposition of X-gal might 
interfere with the antibody binding to the antigen. For electron microsco-
py, portions of the cortex were fixed in 2% glutaraldehyde and post-fixed 
in 1% osmic acid. After embedding, ultrathin sections were stained with 
uranyl acetate and lead citrate.
β-Gal staining and in situ hybridization. β-Gal staining and in situ hybrid-
ization were performed as described previously (26, 66). The probe for in 
situ hybridization of USAG-1 mRNA contained the 1.0-kb open reading 
frame with GC content of 52.6%. Hybridization was detected using an anti-
digoxigenin antibody conjugated with alkaline phosphatase and Nitro blue 
tetrazolium chloride/5-bromo-4-chloro-3-indolyl phosphate, 4-toluidine 
salt (Roche Diagnostics).
Immunoblotting. Whole-kidney tissue was homogenized in RIPA buffer and 
subjected to immunoblotting as previously described (67). The primary anti-
bodies were anti–phospho-Smad1/5/8 (Cell Signaling Technology), phos-
pho-Smad2 (Upstate Biotechnology), and GAPDH (Fitzgerald Industries).
Quantification of mRNA by real-time RT-PCR. Real-time RT-PCR was per-
formed as described previously (27). Specific primers were designed using 
Primer Express software (Applied Biosystems). Serially diluted cDNA was 
used to generate the standard curve for each primer, and the PCR condi-
tions were as follows: 50°C for 2 minutes, 95°C for 10 minutes, then 95°C 
for 15 seconds, and 60°C for 1 minute for 40 cycles.
Cell cultures. Mouse mesangial cells were established from glomeruli iso-
lated from a 4-week-old normal mouse (C57BL/6J) and characterized as 
described previously (68). Cells of passage numbers 18 to 21 were cultured 
in DMEM/F12 containing 20% fetal calf serum.
Assessment of MMP mRNA expression in mesangial cells. Mesangial cells were 
seeded at a concentration of 5 × 104/ml. After 24 hours, the culture medi-
um was replaced with DMEM containing 0.5% bovine serum albumin. The 
cells were incubated for 72 hours with 10 ng/ml MCP-1 (R&D Systems), 
250 pg/ml IL-1β (R&D Systems), or 3 ng/ml TGF-β (R&D Systems) in the 
presence or absence of 20 ng/ml BMP-7 (R&D Systems) and then were ana-
lyzed for MMP mRNA expression by real-time RT-PCR. All experiments 
were performed in quadruplicate.
Production of recombinant USAG-1–Flag protein. A recombinant C-termi-
nally Flag-tagged USAG-1 protein (USAG-1–Flag) was produced using 
the Baculovirus Expression System (Invitrogen) and purified from culture 
medium by affinity absorption on anti-FLAG M2 affinity beads (Sigma-
Aldrich). Protein concentrations were estimated by Coomassie staining.
Zymography. Renal proteins were extracted as previously described (69). 
Samples standardized for protein concentration of 60 μg/lane were elec-
trophoretically separated in 10% SDS-polyacrylamide gels that contained 
1 mg/ml gelatin or α-casein. After separation, gels were placed in 2.5% 
Triton X-100 in PBS, washed, and incubated in developing buffer (50 mM 
Tris, pH 7.5, 200 mM NaCl, 5 mM CaCl2, and 0.02% Brij-35) overnight 
at 37°C. The gels were stained with 0.5% Coomassie blue R250 and then 
destained with a 10% acetic acid, 40% methanol solution until the gelati-
nolytic bands were clearly seen.
Systemic gene transfer. Usag1–/–Col4a3–/– mice were injected with 300 μg of 
pcDNA3.1mUSAG-1 (cDNA for mouse USAG-1 cloned into the pcDNA3.1 
expression vector) into the tibialis anterior muscle at 6 weeks as described 
(70) and were analyzed at 8 weeks for urinary albumin and renal histology.
Statistics. Data are presented as the mean ± SD. Statistical significance was 
assessed by Student’s t test for 2 group comparisons and by ANOVA, fol-
lowed by Fisher’s protected least significant difference post-hoc test for mul-
tiple group comparisons. Significance was defined as a value of P < 0.05.
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